Vical, Inc. (NASDAQ:VICL)

Vical has concluded yet again that patients in the phase III trial of Allovectin-7 are living longer than expected, resulting in another lengthy delay before topline data will be released. Naturally, Vical bulls see this as a positive, concluding that it is an indicator that patients are living longer in the treatment arm. That sounds like an old story that I heard earlier this year with Keryx and perifosine, with an unfortunate outcome for the bulls. I believe I've seen similar outcomes from prolonged phase III trials previously, but I can't remember one where the bull thesis turned out to be correct.

I've seen many phase III clinical trials fail against melanoma. It's a bad cancer to bet against and I won't start with Vical.

"Come on, baby needs a new pair of shoes" Bio spec. Company has products they are selling, insiders buying shares, making deals with BMS, only has around 300 mil market cap, it's priced like a preclinical biotech with dubious products but they are already selling products and have a cancer drug in late stage 3 development. I think this stock is worth double what it's selling for without a successful outcome for the stage 3 trial. But thats up to Mr Market.

Bio play

This stock will definitely outperform the S&P 500. They have great products in Phase 3 ready to be launched so I can only foresee growth.

Biotech play. Like the story.

Technicals

I feel Vical will outperform with needed cash coming from a vaccine recently licensed to Astellas Pharna of Japan. This will improve their revenue as well as the
balance sheet. A hurdle over the hump. I can see
$5 or more within two quarters. Go go long.

Pipeline, pipeline, pipeline- the 3 Ps!

biotech with promising cancer drug in stage III trials

BlackSwanCapital haiku

Third phase data soon

immunotherapeutic

a wunderkind drug

beaten down after last years H1N1 scare, but has opportunity in the viral medicine arena

currently 350 shares in my portfolio.

Unfairly punished for Sanofi's failure (and not Vical's)...

Look for this stock to spike in mid-2011 before results are revealed for the phase III trial of Allovectin-7 in melanoma.

tenmiles

VICL

With many irons in the fire I like their prospects. I really like their emphasis on vaccine production and think that will pan out very well over the next few years.
H1N1 may not have lived up to the hype, but it's only a matter of time before we have a pandemic that does. I think VICL is well positioned for such an event.

@3.41

AS A PHARMACIST I FEEL THE FUTURE IN DRUGS IS IN THE VACINE FIELD, WHICH VICL EXCELS. WITH MONEY FROM MERCK, AND SNY. I FEEL THAT THIS STOCK WILL MOVE UP NEXT YEAR AND FEEL THAT THE SELL OFF THAT IS NOW GOING ON IS A TAX RELIEF SELL OFF.